New T-cell Therapy Targets Multiple Tumor Proteins, Shows Early Survival Gains in Aggressive Pediatric Brain Cancers

Researchers from Children's National Hospital report encouraging early results from a first-in-human clinical trial of a novel T-cell immunotherapy targeting three tumor proteins in children and young adults with devastating brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors. Published in Nature Medicine, these findings are significant because pediatric brain tumors remain the leading cause of cancer-related deaths in children, and immunotherapies have rarely succeeded in treating solid tumors, particularly those in the brain. The therapy works by harnessing the body's immune system to recognize and attack cancer cells expressing specific protein targets. This breakthrough offers new hope for patients with previously difficult-to-treat aggressive brain cancers where conventional treatments have shown limited effectiveness.